Free Newsletter
Novartis plots $700M biotech plant
Novartis will plow $700 million into a new cell-culturing facility in Singapore. The plant will boost the drug maker's capacity for biotech drugs, delivering products for commercial distribution and for clinical development. More than 300 people are expected to work there when it's complete in 2012.
It's Novartis' second big investment in Singapore manufacturing. The company just opened a new $180 million tabletting plant there today; it's expected to employ some 160 workers. Singapore was featured twice on our annual list of the top five regions attracting biotech business.
- check out the report from Channel News Asia
Related Articles:
Novartis injects $816.5M in vaccine plant. Report
Singapore to spend $8B on biotech R&D. Report
GSK opens $13M drug discovery lab in Singapore. Report
Singapore to spend $8B on biotech R&D. Report
GSK blueprints $190M vaccine plant for Singapore. Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment